Related Experiment Video
Updated: Jul 16, 2026
09:44
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Gasdermin D in Neurodegenerative Diseases: Pathogenic Roles and Therapeutic Perspectives
Jiaxin Zhou1,2, Chaolin He1,3, Jianqiao Li1
1Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, China.
Molecular Neurobiology
|July 14, 2026
Summary
Gasdermin D (GSDMD) drives inflammatory cell death and chronic inflammation. Inhibiting GSDMD shows therapeutic potential for neurodegenerative diseases by targeting neuroinflammation and pyroptosis.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Gasdermin D (GSDMD) executes pyroptosis, a programmed inflammatory cell death pathway.
- GSDMD activation leads to pore formation, membrane rupture, and release of inflammatory mediators.
- GSDMD also contributes to chronic inflammation and neutrophil extracellular traps (NETs).
Purpose of the Study:
- To review the role of GSDMD in neurodegenerative diseases (NDDs).
- To explore the therapeutic potential of targeting GSDMD in NDDs.
- To summarize GSDMD inhibitors evaluated in NDD models.
Main Methods:
- Literature review focusing on GSDMD, pyroptosis, neuroinflammation, and NDDs.
- Analysis of cell-type specific GSDMD expression in NDD models.
- Evaluation of therapeutic strategies involving GSDMD inhibition.
Main Results:
- GSDMD plays a pathogenic role in various NDD models.
- Neuroinflammation and pyroptosis are implicated in NDD pathogenesis.
- GSDMD inhibition presents a promising therapeutic avenue for NDDs.
Conclusions:
- GSDMD is a key mediator of neuroinflammation and pyroptosis in NDDs.
- Targeting GSDMD offers a novel therapeutic strategy for neurodegenerative diseases.
- Further research into GSDMD inhibitors could lead to effective NDD treatments.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...